Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14825.203 | 0.9825 | 0.9379 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14825.203 | 0.5443 | -0.3246 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14825.203 | 0.4917 | -0.4364 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14825.203 | 0.3744 | -0.6535 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14825.203 | 0.2494 | -0.8321 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14825.203 | 0.2494 | -0.8321 | 0.5604 | |
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 33.3 | uM | 7824.016 | 0.2885 | -0.0307 | 1.7164 | ||
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14825.203 | 0.2015 | -0.8853 | 0.5604 | |
| EFM-192A | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 15284.203 | 1.0045 | 1.0129 | 0.6980 | |
| EFM-192A | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 15284.203 | 0.8924 | 0.6989 | 0.6980 | |
| EFM-192A | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 15284.203 | 0.6473 | 0.0726 | 0.6980 | |
| EFM-192A | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 15284.203 | 0.3771 | -0.5053 | 0.6980 | |
| EFM-192A | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 15284.203 | 0.2271 | -0.7609 | 0.6980 | |
| EFM-192A | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 15284.203 | 0.2271 | -0.7609 | 0.6980 | |
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 167 | uM | 7824.016 | 0.8217 | 0.7838 | 1.7164 | ||
| AU565 | HER2amp | Luminal | AG1024 | IGF1R | RTK | 0.0000853 | uM | 5900.066 | 1.0491 | 1.0355 | 2.7232 | |
| AU565 | HER2amp | Luminal | AG1024 | IGF1R | RTK | 0.00213 | uM | 5900.066 | 0.9888 | 0.9917 | 2.7232 | |
| EFM-192A | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 15284.203 | 0.2161 | -0.7772 | 0.6980 | |
| EFM-192B | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 15288.203 | 1.0261 | 1.0666 | 0.7873 | |
| EFM-192B | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 15288.203 | 1.0261 | 1.0666 | 0.7873 | |
| EFM-192B | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 15288.203 | 0.9665 | 0.9153 | 0.7873 | |
| EFM-192B | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 15288.203 | 0.8966 | 0.7412 | 0.7873 | |
| HCC1569 | HER2amp | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 0.000427 | uM | 7825.016 | 0.9623 | 0.9542 | 1.6601 | ||
| EFM-192C | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15292.203 | 0.0516 | -0.7075 | 1.5415 | |
| EFM-192C | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15292.203 | 0.0516 | -0.7075 | 1.5415 |